eFFECTOR Therapeutics

Pioneering the discovery and development of selective translation regulators to harness the body’s ability to fight cancer.

[eFFECTOR Therapeutics @eFFECTOR_Rx]

We’re exploring multiple opportunities combining zotatifin with targeted agents in ER+ breast cancers and other hormone-driven cancers. Learn more: https://t.co/44iYyzNeP0

[eFFECTOR Therapeutics @eFFECTOR_Rx]

We are advancing our pipeline of Selective Translation Regulator Inhibitors (STRIs) as potential new treatments for #cancer. Check out our website to learn more: https://t.co/mTu9KF5U6n

[eFFECTOR Therapeutics @eFFECTOR_Rx]

On #NationalCancerSurvivorsDay, we salute the strength and resilience of cancer survivors everywhere. At eFFECTOR, we're dedicated to supporting survivors through the development of innovative new treatments.

[eFFECTOR Therapeutics @eFFECTOR_Rx]

The eFFECTOR team will be attending the @ASCO Annual Meeting from May 31 to June 4 in Chicago, Illinois. We look forward to connecting with our industry peers at #ASCO24! Learn more: https://t.co/Y3zFCPDPal

[eFFECTOR Therapeutics @eFFECTOR_Rx]

We're thrilled to start an investigator-sponsored trial evaluating our lead product candidate in patients with estrogen receptor-positive (ER+) endometrial and ovarian cancers, collaborating with the @DanaFarber Cancer Institute. Read more: https://t.co/lYiLvV2COZ

[eFFECTOR Therapeutics @eFFECTOR_Rx]

We will be participating in the A.G.P.'s Virtual Healthcare Company Showcase on May 22. We look forward to engaging in one-on-one discussions with investors regarding eFFECTOR’s unique targeted approach to treating cancer. Learn more:https://t.co/kCImrHZ0Yn

[eFFECTOR Therapeutics @eFFECTOR_Rx]

#WomensHealthMonth serves as a reminder to take care of your overall health and make it a priority in your life. Here at eFFECTOR, we are proud to be developing a product candidate for breast cancer, which affects women all around the world.

[eFFECTOR Therapeutics @eFFECTOR_Rx]

We are advancing our product candidate zotatifin in ER+ #BreastCancer. Read more about our #ClinicalTrials on our website: https://t.co/rW2AGfb6mJ

[eFFECTOR Therapeutics @eFFECTOR_Rx]

Our CEO, Steve Worland, PhD, recently joined the @DDWJournal podcast to speak about our pipeline and future endeavors. Tune in as they delve into the innovative strategies shaping the future of oncology. Listen to the episode here: https://t.co/FNz3lvIo9Q

[eFFECTOR Therapeutics @eFFECTOR_Rx]

We will be presenting tomorrow at the Stifel 2024 Virtual Targeted Oncology Forum at 11:30 AM ET. A live webcast of the virtual presentation will be available. Read more: https://t.co/9sGASWu5Tq

[eFFECTOR Therapeutics @eFFECTOR_Rx]

Our team was founded by industry veterans who have played important roles in discovering and developing various findings in #oncology and other disease areas. Thank you to the doctors who evaluate and treat our areas of focus. #NationalDoctorsDay

[eFFECTOR Therapeutics @eFFECTOR_Rx]

Our CEO, Steve Worland, PhD, spoke with Benjamin Burnett, PhD, of @Stifel, about our product candidate for the treatment of patients with non-small cell #LungCancer. Listen to the full chat here: https://t.co/0al4leha7w $EFTR

[eFFECTOR Therapeutics @eFFECTOR_Rx]

This #PatientSafetyAwarenessWeek, we emphasize the importance of patient safety during #ClinicalTrials. At eFFECTOR, our passion is using the best science to develop better medicines to treat cancer – including by conducting clinical trials. Learn more: https://t.co/oxPY1rPJk7

[eFFECTOR Therapeutics @eFFECTOR_Rx]

Ahead of anticipated data from our Phase 2b KICKSTART study, learn about our lead Selective Translation Regulator Inhibitor (STRI) for patients with non-small cell lung cancer (#NSCLC). Read more on our website: https://t.co/W7Ir3CNXZf $EFTR

[eFFECTOR Therapeutics @eFFECTOR_Rx]

This snapshot from our recent Virtual R&D Day showcases the importance of addressing the #UnmetNeed in treatment for those with cancer. Listen now, and see more about the potential impact of our technology, here: https://t.co/Buaem8zjvp $EFTR

[eFFECTOR Therapeutics @eFFECTOR_Rx]

At our recent Virtual R&D Day, Dr. Kevin Kalinsky discussed how our Selective Translation Regulator Inhibitor (STRI) shows promise in endocrine receptor-positive #BreastCancer as a potential combination therapy. Stay tuned for more insights! $EFTR

[eFFECTOR Therapeutics @eFFECTOR_Rx]

Our Chief Medical Officer, Dr. Doug Warner, brings passion and expertise to our leadership team with his experience in solid tumor immune-oncology and pathway inhibitor development programs. Read more about Doug and our team, here: https://t.co/E4XKh61lJN

[eFFECTOR Therapeutics @eFFECTOR_Rx]

#DYK more than 1 in 5 people will be diagnosed with cancer in their lifetime? That is why this #WorldCancerDay and beyond, we are steadfast in our mission to deprive cancer of what it needs to give patients what they need. Read about our oncology pipeline: https://t.co/0tYzMNG6N9

[eFFECTOR Therapeutics @eFFECTOR_Rx]

Our President & CEO, Steve Worland, will be presenting at the Chemical Biology Consortium Symposium, co-hosted by @theNCI and @sbpdiscovery, today at 2:10pm. His presentation will cover our novel approach to #CancerTherapy, focused on STRIs. Learn more: https://t.co/8kxjlb3Mmt

[eFFECTOR Therapeutics @eFFECTOR_Rx]

The eFFECTOR leadership team has a deep understanding of translation regulation biology and oncology drug development. We asked our CEO, Steve Worland why he’s proud to lead our team as we pioneer the development of first in class #oncology drugs.